

Association of Risk Estimates of Three Different Cardiovascular Risk Assessment Tools with Carotid Intima Media Thickness in Patients with Type 2 Diabetes

HERATH MUDIYANSELAGE METHTHANANDA HERATH¹, THILAK PRIYANTHA WEERARATHNA², RANASINGHE BETHMI ARACHIGE THILINI DULANJALEE³, MADUMEKALA RUPASINGHE JAYAWARDANA⁴, UDARA PRIYADARSHANI EDIRISINGHA⁵, MADUSHANKA RATHNAYAKE⁶

ABSTRACT

Introduction: Risk assessment tools used to calculate the Cardiovascular Disease (CVD) risk such as the Framingham Risk Score (FRS), United Kingdom Prospective Diabetes study (UKPDS) risk engine and the World Health Organization (WHO) risk score have not been tested on their ability to detect subclinical atherosclerosis in most developing countries.

Aim: To study the association between the calculated CVD risk scores using each of these tools and Carotid Intima Medial Thickness (CIMT), a surrogate marker of atherosclerosis, in a group of patients with Type 2 diabetes (T2DM) in Sri Lanka.

Materials and Methods: We calculated CVD risk scores of 68 randomly selected patients with T2DM with no history or symptoms of CVD and measured their CIMT using B-mode ultrasonography (USS). Carotid USS was considered positive when the maximum carotid IMT was 0.9mm or when arteriosclerotic plaques were detected. The 10-year CVD risk was calculated using the FRS, the UKPDS risk engine and the

WHO risk score. Pearson correlation was used to study the association between CVD risk scores with CIMT.

Results: Of the 68 patients studied, 50% were males and their mean age (SD) was 56.9 (± 9.6) years. The mean age at onset and duration of diabetes were 44.3(± 9.1) and 12.2(± 7.6) years respectively. Of the scoring methods, UKPDS tool had weak, but significantly positive ($r = 0.26$, $p < 0.05$) and FRS had positive but not significant association ($r = 0.21$) with CIMT. There was a negative association between CIMT and WHO risk score ($r = -0.07$).

Conclusion: Of the three CVD risk assessment tools, both UKPDS risk engine and FRS have almost equal ability (former being marginally superior) in predicting underlying atherosclerotic vascular disease in patients with T2DM. Negative association of the WHO risk score with CIMT argues against its utility for CVD screening. These findings highlight the need for developing more sensitive and reliable CVD risk assessment tools for developing countries.

Keywords: Cardiac risk prediction, Framingham risk score, United kingdom prospective diabetes study risk engine, World health organization risk score

INTRODUCTION

South Asian countries are facing an epidemic of non-communicable diseases including Type 2 Diabetes and Cardiovascular Diseases (CVD) [1]. Individuals with type 2 diabetes (T2DM) have two to four-fold increased risk of Cardiovascular Disease (CVD) than the non-diabetic individuals [2,3]. Estimation of cardiovascular risk in asymptomatic individuals and their referral for necessary preventive interventions is an important measure to reduce CVD morbidity and mortality [4].

Assessment of CVD risk is usually carried out by looking for measureable risk markers such as age, gender, total cholesterol level, systolic blood pressure and smoking status and then uses these markers to calculate the ten year risk of a vascular event as a percentage probability. Ten-year risk estimates may serve not only as a basis for decision making about institution of various preventive therapy but also as a useful means for risk communication with patients. Framingham Risk Score (FRS), United Kingdom Prospective Diabetes Study (UKPDS) risk engine and the risk score developed by the World Health Organization (WHO) are three widely used cardiovascular risk assessment tools in clinical and epidemiological research. The first two assessment tools are derived from, data from the Framingham and UKPDS studies which predominantly included Caucasian population [5,6]. WHO risk score is derived from data collected in few cohorts in developing countries including Asia and it is primarily meant to be used in resource poor setting [7]. As these risk assessment tools are developed using data of patients in different ethnic settings,

their global applicability may be limited. Number of studies have shown that even in the correct setting these risk scores can either underestimate or overestimate the real cardiac risk [8,9]. A study conducted in multi-ethnic population in the United Kingdom has revealed that FRS underestimated the CVD risk in South Asian females [10]. Another study among the high-risk South Asians revealed that FRS could categorise only 5% of the population into the high CVD risk (>20%) category [11]. Although the WHO risk charts are developed for most regions of the world, only few studies have reported its performance in resource poor setting in developing countries.

Even though the accuracy of risk prediction tools should be assessed by observing cardiac events over many years, it may not be practical. Since Carotid Intima-Media Thickness (CIMT) has been shown to predict Cardiovascular (CV) events in multiple large studies, ability of the risk prediction tools to predict CIMT can be used to assess the accuracy of these tools [12]. The amount of lesion in the Common Carotid Artery (CCA) has been reported to correlate to the extent of atherosclerotic lesions elsewhere in the body including the heart. Several large, research-based cohort studies have clearly indicated a relationship between CIMT and CV events [13].

AIM

We aimed to study the associations between CIMT and the CVD risk estimates obtained using the three risk assessment tools in a cohort of patients with diabetes mellitus.

MATERIALS AND METHODS

The present work was undertaken at Department of Medicine, Faculty of Medicine, University of Ruhuna, Sri Lanka during the period from January 2014 to January 2015. The study subjects were selected from a community-derived sample of patients with Type 2 Diabetes Mellitus. Patients were excluded if they had any previous history of ischaemic stroke, hypertension, familial hyperlipidaemia, history of angina, myocardial infarction, angioplasty, congestive heart failure, atrial fibrillation, coronary artery bypass, carotid or peripheral vascular surgery, or renal insufficiency. Sixty eight patients fulfilled inclusion criteria for the study. Patients receiving oral hypoglycaemic agents, antihypertensive, and antiplatelet agents were not excluded from the study.

The study protocol was approved by the Ethics Review Committee (ERC) of Faculty of Medicine, University of Ruhuna and written informed consent was obtained from all participants.

Data Collection and Risk Factor Definition

Information on demographic characteristics and risk factors was collected using a pre-tested structured questionnaire. Blood pressure was measured in a sitting position, and hypertension treatment at admission was recorded. Hypertension was defined as having systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg on two or more occasions or having treatment for hypertension. Blood was drawn in the morning from fasting subjects for blood sugar and lipid profile determination. Low-Density Lipoprotein (LDL) cholesterol was calculated by the Friedewald formula. Subjects were classified as diabetic when their fasting blood sugar values were ≥ 126 mg/dL, or post prandial blood sugar ≥ 200 mg/dL and/ or on treatment for diabetes with medications.

CIMT Measurement

Carotid ultrasonography studies were performed uniformly on all patients by a single radiologist who was blinded to the CVD risk scores of study subjects. Ultrasonography was performed with B-mode images of a high-resolution ultrasound scanner equipped with a 7 MHz linear array transducer. Anterior, antero-lateral, and postero-lateral projections were used to obtain images of the left and right common and internal carotid arteries. CIMT was measured according to the standard protocol and the presence of carotid plaques were documented at the same time.

CVD Risk Assessment

CVD risk scores according to the FRS, UKPDS risk engine and WHO system were calculated separately using the information on clinical and laboratory findings. The correlations between each risk score with CIMT were estimated using Pearson's correlation and p-value of <0.05 was considered as statistically significant.

STATISTICAL ANALYSIS

While all qualitative variables were presented in frequency or percentages, all quantitative variables were presented in the form of mean and standard deviation (SD). T-tests and chi-square tests were performed to compare the differences in groups. Pearson correlation analyses were used to evaluate associations between CIMT and CVD risk score detected by three risk scores. CIMT was log transformed as it was not normally distributed. All analyses were two-tailed and <0.05 was considered statistically significant. Statistical analyses were performed using the SPSS version 18.0.

RESULTS

There were 68 patients (50%males) with mean (SD) age 56.6 (± 9.6) years, mean age at diagnosis 44.2 (± 9) years and mean duration of diabetes was 12.2 (± 7.6) years [Table/Fig-1]. The mean HbA1c was 7.3%. Of the total 66% and 90% of study participants were on anti-hypertensive and lipid lowering therapy respectively.

Variable	Mean (\pm SD)
Age (years)	56.59 (± 9.63)
Age at diagnosis (years)	44.26 (± 9.01)
BMI (Kg / m ²)	24.33 (± 3.23)
Duration (years)	12.16 (± 7.66)
HbA1C (%)	07.30 (± 0.77)

[Table/Fig-1]: Characteristics of study sample. SD – Standard Deviation, HbA1c-Glycated haemoglobin, LDL – Low Density Lipoprotein, TG-Triglyceride.

[Table/Fig-2] shows the correlation between CIMT and different variables. Among all variables CIMT had significant and positive association with duration of T2DM and HbA1c level. The other variables too showed positive association even though they did not reach the statistical significance.

Variable	r value	p-value
Age	0.149	0.083
Duration of T2DM	0.194	0.041*
BMI	0.097	0.450
HbA1c	0.284	0.027*
Total cholesterol	0.065	0.596
LDL	0.138	0.265
TG	0.028	0.824

[Table/Fig-2]: Correlation between CIMT with different variables including age, duration of T2DM, HbA1c, total cholesterol, LDL, and TG. *p-value is significant at <0.05 , CIMT - Carotid Artery Intima Media Thickness, T2DM-Type 2 Diabetes Mellitus, HbA1c-Glycated Haemoglobin, LDL – Low Density Lipoprotein, TG-Triglyceride.

As shown in [Table/Fig-3], the WHO risk score categorised considerably higher proportion (97%) of patient into low cardiac risk ($<10\%$) whereas, both FRS and UKPDS risk scores categorised lower proportions into low risk category.

	$<10\%$	10%-20%	21%-30%	$>30\%$
WHO	97.1%	00 %	1.5%	1.5%
FRS	36.76%	38.25%	16.17%	8.82%
UKPDS	54.41%	35.29%	4.41%	5.88%


[Table/Fig-3]: Percentages of study subjects in each risk category according to three risk estimation tools. FRS-Framingham risk score, UKPDS- United Kingdom Prospective Diabetes Study risk engine, WHO -World Health Organization

Twelve of the 68 (17%) patients had ultrasonically detectable carotid plaques. Out of the three CVD risk estimation tools, UKPDS risk score revealed a weakly positive but significant correlation with CIMT ($r=0.26$, $p=0.03$). FRS also had weakly positive but statistically non-significant association ($r=0.2$, $p=0.08$) and WHO risk score had non-significant negative association ($r=-0.06$, $p=0.5$) with CIMT. [Table/Fig-4] shows the association of FRS, WHO, UKPDS scores with CIMT.

In order to find the degree of agreement of CVD risk estimates into low or high category ($< 10\%$ and $> 10\%$) obtained from each screening tool, we calculated Cohen's kappa value and found that FRS and UKPDS risk estimates have moderate degree of agreements and WHO tool has poor degree of agreements with both FRS and UKPDS, with a kappa value of 0.5 and 0.04, 0.02 respectively [Table/Fig-5].

DISCUSSION

Rising incidence of CVD in the developing countries has necessitated adoption of primary prevention approaches aimed at controlling risk factors to reduce cardiovascular morbidity and mortality. This approach needs sensitive and cost-effective screening tools to identify asymptomatic individuals with higher



[Table/Fig-4]: Scatter plots showing the association of FRS, WHO and UKPDS scores with CIMT.

FRS-Framingham Risk Score, UKPDS- United Kingdom Prospective Diabetes Study risk engine, WHO-World Health Organization, CIMT -carotid artery intima media thickness

	Kappa value	Asymp. SE	Approx. Sig.
FRS and UKPDS	0.540	0.095	0.000
WHO and UKPDS	0.070	0.048	0.117
WHO and FRS	0.035	0.025	0.274

[Table/Fig-5]: Agreement of different risk factor combinations.

FRS-Framingham risk score, UKPDS- United Kingdom Prospective Diabetes Study risk engine, WHO -World Health Organization.

risk and/or subclinical CVD in the community. Different risk scoring systems have been developed for this purpose. However, due to marked variations in risk profiles due to difference in culture and lifestyle, these risk scores cannot be applied to all ethnic groups equally. Furthermore, studies have found that the most CVD risk scores, which were developed mainly for Caucasians, underestimate the cardiac risk among South Asians. Even though WHO risk score for South Asia is derived from locally collected data, it has not been tested on its ability to detect subclinical atherosclerosis among patients with T2DM in Sri Lanka.

Findings of this study revealed that FRS and UKPDS risk engines are better CVD screening tools to detect subclinical atherosclerosis than the WHO risk score in a cohort of Sri Lankan patients with T2DM. Ability of a CVD risk scoring tool to detect individuals with high risk of CVD in a given setting depends on several factors. Out of them, variables (risk factors) used in each tool to calculate CVD risk and the relative weightage given to each of them are important. Three CVD risk screening tools compared in this study differ in the variables included in them. Age, gender, smoking status and systolic blood pressure are common to all three tools but the UKPDS risk engine in addition include ethnicity, duration of diabetes, glycosylated haemoglobin level and the FRS include high density cholesterol level. Findings of this study revealed that inclusion of additional parameters have improved the detection rates of individuals at all cut-off levels in both FRS and UKPDS tools.

Few studies have reported on the ability of UKPDS risk engine to predict subclinical atherosclerosis in Asian populations. A Korean study which investigated the ability of UKPDS risk engine and FRS in predicting CIMT of 621 patients with T2DM has reported that the former had the highest odds ratios of detecting Korean individuals with carotid atherosclerosis [14]. Previous studies done in Sri Lanka and Oman have reported that the FRS compared to WHO risk score categorized more individuals into low cardiac risk category of <10% [15,16]. These findings suggest that the WHO tool is relatively less sensitive in detecting individuals with low to moderate CVD risk than the FRS. A study conducted in three developing countries including Mongolia, Malaysia and Cambodia

have reported that using the WHO risk score, the percentages in the risk category > 20% were 6%, 2.3% and 1.3 % respectively, indicating its lower detection rates of individuals with high CVD risk [17].

The possible explanation for both UKPDS and FRS to reveal stronger associations with CIMT than the WHO tool could be due to inclusion of additional variables such as HDL cholesterol, glycated haemoglobin and duration of diabetes in them. Studies have shown higher prevalence rates of lower HDL cholesterol among Indian Asians [18]. Higher CVD morbidity and mortality in the South Asian region is postulated to be associated with lower HDL level [19]. Markedly lower percentages of individuals in the CVD risk categories of > 10% with WHO risk score suggests the relative lack of sensitivity of including the total cholesterol level alone in predicting the CVD risk in Asian ethnicity.

The observed degree of agreement of the UKPDS and FRS are moderate with Cohen's kappa value of 0.5 [Table/Fig-3]. Although the WHO risk estimation tool is meant to be used in the developing countries with poor resources, findings of this study argues against its reliability in detecting individuals who need primary prevention strategies in this setting. Instead, both UKPDS and FRS which are derived from data from Caucasian population, revealed better yield of patients with risk level above cut-off levels 10% and 20%. Adoption of WHO risk estimation tool in resource poor settings may incur low costs, but the price these communities will have to pay by denying the evidence based therapy such as statins and aspirin for needy patients could be costly. Instead of the WHO tool, use of either FRS or UKPDS risk assessment tool could detect a higher percentage of patients with CVD risk levels of > 10% and 10-20%.

This is the first study from our country to reveal the association of risk estimates of CVD risk estimation tools with a surrogate marker of atherosclerosis. However, there are few limitations in this study. The main limitation of this study is the sample size. As we used clinical evidence of established CVD in excluding patients for CIMT measurement, it is possible that some patients with established CVD without symptoms may have been included inadvertently for CIMT testing. We studied only the patients with diabetes hence, these findings may not be applicable to individuals without diabetes. Despite these limitations, we believe our findings would serve as an eye opener for public health authorities in the developing countries in selecting and adopting sensitive risk estimation method to screen asymptomatic individuals with diabetes for necessary primary prevention strategies.

CONCLUSION

We reported relative lack of sensitivity of WHO risk assessment tool compared to FRS and UKPDS risk engines to detect subclinical atherosclerosis among individuals with T2DM in a developing country. The CVD risk scores obtained by the latter two risk assessment tools had positive but weak associations with a surrogate marker of atherosclerosis and moderate agreement between them.

ACKNOWLEDGMENTS

The authors would like to thank the participants of this study, all the staff of the Diabetes Centre, Galle and consultants who kindly provided consent for their patients to be used. A special word of thanks is extended to KM Kumuduni de Silva and KSM Weeraratna for laboratory assistance and Dr SP Mohotti, and Dr CM De Silva for their assistance in conducting this study.

REFERENCES

- [1] Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. *Diab Care*. 2011;34(6):1249-57.
- [2] Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. *Diab Care*. 1979;2(2):120-26.
- [3] Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diab Care*. 1993;16(2):434-44.
- [4] Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. *Circulation*. 2010;121(15):1768-77.
- [5] Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. *The Am JCardiol*. 2004;94(1):20-24.
- [6] Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clinical Science (London, England : 1979)*. 2001;101(6):671-79.
- [7] Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. *J Hypertens*. 2007;25(8):1578-82.
- [8] Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. *Diab med: A Journal of the British Diabetic Association*. 2005;22(5):554-62.
- [9] Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, et al. Performance of the UK prospective diabetes study risk engine and the framingham risk equations in estimating cardiovascular disease in the epic-norfolk cohort. *Diab Care*. 2009;32(4):708-13.
- [10] Tillin T, Hughes AD, Whincup P, Mayet J, Sattar N, McKeigue PM, et al. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE--Southall And Brent REvisited). *Heart*. 2014;100(1):60-67.
- [11] Kanjilal S, Rao VS, Mukherjee M, Natesha BK, Renuka KS, Sibi K, et al. Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. *Vasc Health Risk Manag*. 2008;4(1):199-211.
- [12] Rubinat E, Marsal JR, Vidal T, Cebrian C, Falguera M, Vilanova MB, et al. Subclinical carotid atherosclerosis in asymptomatic subjects with type 2 diabetes mellitus. *The J Cardiovasc Nurs*. 2016;31(2):E1-7.
- [13] Kasliwal RR, Bansal M, Desai D, Sharma M. Carotid intima-media thickness: Current evidence, practices, and Indian experience. *Indian J Endocr Metab*. 2014;18(1):13-22.
- [14] Ahn HR, Shin MH, Yun WJ, Kim HY, Lee YH, Kweon SS, et al. Comparison of the Framingham Risk Score, UKPDS Risk Engine, and SCORE for Predicting Carotid Atherosclerosis and Peripheral Arterial Disease in Korean Type 2 Diabetic Patients. *Korean J Fam Med*. 2011;32(3):189-96.
- [15] Al-Lawati JA, Barakat MN, Al-Lawati NA, Al-Maskari MY, Elsayed MK, Mikhailidis DP, et al. Cardiovascular risk assessment in diabetes mellitus: comparison of the general Framingham risk profile versus the World Health Organization/International Society of Hypertension risk prediction charts in Arabs--clinical implications. *Angiology*. 2013;64(5):336-42.
- [16] Herath HMM, Weeraratna TP, Umsha D. Cardiovascular risk assessment in type 2 diabetes mellitus: comparison of the World Health Organization/International Society of Hypertension risk prediction charts versus UK Prospective Diabetes Study risk engine. *Vasc Health Risk Manag*. 2015;11:583-89.
- [17] Otgontuya D, Oum S, Buckley BS, Bonita R. Assessment of total cardiovascular risk using WHO/ISH risk prediction charts in three low and middle income countries in Asia. *BMC Public Health*. 2013;13:539.
- [18] Ewang-Emukowhate M, Perera D, Wierzbicki AS. Dyslipidaemia related to insulin resistance and cardiovascular disease in south asian and west african populations. *Curr Pharm Des*. 2014;20(40):6270-75.
- [19] Ina K, Hayashi T, Araki A, Kawashima S, Sone H, Watanabe H, et al. Importance of high-density lipoprotein cholesterol levels in elderly diabetic individuals with type IIb dyslipidemia: A 2-year survey of cardiovascular events. *Geriatr Gerontol Int*. 2014;14(4):806-10.

PARTICULARS OF CONTRIBUTORS:

1. Senior Lecturer, Department of Medicine, Faculty of Medicine, Galle University of Ruhuna, Srilanka.
2. Professor, Department of Medicine, Faculty of Medicine, Galle University of Ruhuna, Galle, Srilanka.
3. Demonstrator, Department of Medicine, Faculty of Medicine, Galle University of Ruhuna, Galle, Srilanka.
4. Demonstrator, Department of Medicine, Faculty of Medicine, Galle University of Ruhuna, Galle, Srilanka.
5. Demonstrator, Department of Medicine, Faculty of Medicine, Galle University of Ruhuna, Galle, Srilanka.
6. Demonstrator, Department of Medicine, Faculty of Medicine, Galle University of Ruhuna, Galle, Srilanka.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Herath Mudiyansele Meththananda Herath,
Senior Lecturer, Department of Medicine, Faculty of Medicine, PO Box 70, Galle, Srilanka.
E-mail: herathtp@gmail.com

Date of Submission: **Feb 08, 2016**
Date of Peer Review: **Mar 29, 2016**
Date of Acceptance: **Apr 19, 2016**
Date of Publishing: **Jul 01, 2016**

FINANCIAL OR OTHER COMPETING INTERESTS: None.